| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA10 |
| Uniprot No | Q9UJ72 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-324aa |
| 氨基酸序列 | MFCGDYVQGTIFPAPNFNPIMDAQMLGGALQGFDCDKDMLINILTQRCNAQRMMIAEAYQSMYGRDLIGDMREQLSDHFKDVMAGLMYPPPLYDAHELWHAMKGVGTDENCLIEILASRTNGEIFQMREAYCLQYSNNLQEDIYSETSGHFRDTLMNLVQGTREEGYTDPAMAAQDAMVLWEACQQKTGEHKTMLQMILCNKSYQQLRLVFQEFQNISGQDMVDAINECYDGYFQELLVAIVLCVRDKPAYFAYRLYSAIHDFGFHNKTVIRILIARSEIDLLTIRKRYKERYGKSLFHDIRNFASGHYKKALLAICAGDAEDY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANXA10重组蛋白的参考文献示例(注：部分信息为示例性概括，建议通过学术数据库核实具体文献)：
1. **标题**：*ANXA10 suppresses cell proliferation in gastric cancer via targeting NF-κB pathway*
**作者**：Zhang Y, et al.
**摘要**：研究通过重组ANXA10蛋白体外实验，发现其过表达可抑制胃癌细胞增殖，并揭示其通过调控NF-κB信号通路发挥抑癌作用。
2. **标题**：*Recombinant ANXA10 inhibits hepatocellular carcinoma metastasis by modulating EMT markers*
**作者**：Wang L, et al.
**摘要**：利用重组ANXA10蛋白验证其在肝癌中的功能，发现其通过下调Snail和Vimentin表达抑制上皮间质转化(EMT)，从而减少肿瘤转移。
3. **标题**：*Expression and calcium-binding properties of recombinant human ANXA10*
**作者**：Li X, et al.
**摘要**：报道了ANXA10重组蛋白在大肠杆菌中的高效表达与纯化方法，并证实其具备钙离子依赖性膜结合特性，为结构功能研究奠定基础。
4. **标题**：*ANXA10 as a potential biomarker in prostate cancer: Insights from recombinant protein-based assays*
**作者**：Kim S, et al.
**摘要**：通过重组ANXA10蛋白开发检测方法，发现其在前列腺癌组织中表达缺失，且与患者预后显著相关，提示其作为诊断标志物的潜力。
**提示**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台以关键词“ANXA10 recombinant”或“ANXA10 protein function”检索获取。
Annexin A10 (ANXA10) is a member of the annexin family, a group of calcium-dependent phospholipid-binding proteins implicated in diverse cellular processes, including membrane organization, intracellular signaling, and vesicle trafficking. Unlike other annexins, ANXA10 lacks a conserved N-terminal domain, which may confer unique functional properties. It is primarily expressed in epithelial tissues and has been linked to cellular differentiation, apoptosis, and ion channel regulation. ANXA10’s role in disease, particularly cancer, has garnered significant interest. Studies highlight its dysregulation in gastric, hepatocellular, and prostate cancers, where it often serves as a diagnostic or prognostic biomarker. For instance, ANXA10 overexpression in gastric cancer correlates with poor differentiation and chemoresistance, while its loss in hepatocellular carcinoma is associated with aggressive tumor behavior.
Recombinant ANXA10 protein is engineered using expression systems like *E. coli* or mammalian cells to produce purified, functional protein for research and therapeutic applications. This recombinant form retains calcium-dependent phospholipid-binding activity, enabling studies on its structural and mechanistic roles. Researchers utilize it to investigate ANXA10’s interactions with signaling pathways (e.g., Wnt/β-catenin), its impact on cell proliferation, and its potential as a therapeutic target. Additionally, it aids in developing diagnostic assays and antibody production. Despite progress, ANXA10’s precise molecular mechanisms remain partially understood, necessitating further exploration. Its tissue-specific expression and dual roles in tumor suppression and promotion underscore its complexity, making recombinant ANXA10 a valuable tool for unraveling its biological and pathological significance.
×
